MX2010009753A - Composiciones que contienen apoaecuorina y metodos de uso de las mismas. - Google Patents

Composiciones que contienen apoaecuorina y metodos de uso de las mismas.

Info

Publication number
MX2010009753A
MX2010009753A MX2010009753A MX2010009753A MX2010009753A MX 2010009753 A MX2010009753 A MX 2010009753A MX 2010009753 A MX2010009753 A MX 2010009753A MX 2010009753 A MX2010009753 A MX 2010009753A MX 2010009753 A MX2010009753 A MX 2010009753A
Authority
MX
Mexico
Prior art keywords
methods
apoaequorin
same
quality
containing compositions
Prior art date
Application number
MX2010009753A
Other languages
English (en)
Inventor
Mark Y Underwood
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of MX2010009753A publication Critical patent/MX2010009753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan por la presente invención composiciones las cuales contienen apoaecuorina y métodos para uso en tratamiento de síntomas y trastornos relacionados a desequilibrios de calcio asociados con, por ejemplo, calidad del sueño, calidad de energía, calidad de humor, calidad de memoria o dolor.
MX2010009753A 2008-03-11 2009-03-11 Composiciones que contienen apoaecuorina y metodos de uso de las mismas. MX2010009753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3544308P 2008-03-11 2008-03-11
PCT/US2009/036767 WO2009114597A1 (en) 2008-03-11 2009-03-11 Apoaequorin-containing compositions and methods of using same

Publications (1)

Publication Number Publication Date
MX2010009753A true MX2010009753A (es) 2010-09-30

Family

ID=40627496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009753A MX2010009753A (es) 2008-03-11 2009-03-11 Composiciones que contienen apoaecuorina y metodos de uso de las mismas.

Country Status (19)

Country Link
US (1) US8796213B2 (es)
EP (1) EP2262525B1 (es)
JP (1) JP5508294B2 (es)
KR (1) KR101643662B1 (es)
CN (2) CN101969979A (es)
AU (1) AU2009223010B2 (es)
BR (1) BRPI0909435A2 (es)
CA (1) CA2717322C (es)
CY (1) CY1114366T1 (es)
DK (1) DK2262525T3 (es)
ES (1) ES2401754T3 (es)
HR (1) HRP20130205T1 (es)
IL (1) IL207827A (es)
MX (1) MX2010009753A (es)
NZ (1) NZ588437A (es)
PL (1) PL2262525T3 (es)
PT (1) PT2262525E (es)
SI (1) SI2262525T1 (es)
WO (1) WO2009114597A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2780027T3 (en) * 2011-11-15 2017-09-25 Quincy Bioscience Llc Apoaequorin for limiting ischemia-induced nerve damage.
PT2900253T (pt) * 2012-09-27 2019-02-25 Quincy Bioscience Llc Métodos para aliviar os sintomas da esclerose múltipla baseados em composições contendo apoequorina
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
JP2019532936A (ja) * 2016-09-23 2019-11-14 クインシー バイオサイエンス，リミティド ライアビリティ カンパニー アポエクオリンおよびビタミンｄ含有組成物およびそれらの使用方法
AU2021225815A1 (en) * 2020-02-24 2022-09-08 Quincy Bioscience, Llc Apoaequorin and curcumin containing compositions and methods
JP2023538917A (ja) * 2020-08-20 2023-09-12 クインシー バイオサイエンス，リミティド ライアビリティ カンパニー アポイクオリンを含む発泡性組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6447379A (en) * 1987-08-19 1989-02-21 Chisso Corp Preparation of calcium-dependent oxygenation enzyme
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
CN1324045C (zh) * 2004-09-22 2007-07-04 中国科学院海洋研究所 从水母中分离的具有抗氧化活性的蛋白及其应用

Also Published As

Publication number Publication date
WO2009114597A1 (en) 2009-09-17
US20110124562A1 (en) 2011-05-26
PL2262525T3 (pl) 2013-04-30
KR101643662B1 (ko) 2016-07-29
DK2262525T3 (da) 2013-02-11
SI2262525T1 (sl) 2013-03-29
AU2009223010A1 (en) 2009-09-17
CY1114366T1 (el) 2016-08-31
KR20100136494A (ko) 2010-12-28
US8796213B2 (en) 2014-08-05
AU2009223010B2 (en) 2014-01-09
IL207827A (en) 2013-08-29
JP2011513496A (ja) 2011-04-28
CA2717322C (en) 2017-07-11
ES2401754T3 (es) 2013-04-24
EP2262525B1 (en) 2012-12-26
IL207827A0 (en) 2010-12-30
BRPI0909435A2 (pt) 2017-06-13
CN101969979A (zh) 2011-02-09
CN106692945A (zh) 2017-05-24
CA2717322A1 (en) 2009-09-17
PT2262525E (pt) 2013-01-28
JP5508294B2 (ja) 2014-05-28
EP2262525A1 (en) 2010-12-22
NZ588437A (en) 2012-07-27
HRP20130205T1 (hr) 2013-04-30

Similar Documents

Publication Publication Date Title
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2012020307A3 (en) Therapeutic uses of microvesicles and related micrornas
MX2011007930A (es) Conjugados de insulina cristalina.
MX2011010449A (es) Derivados de oxadiazol.
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
MX2010007490A (es) Preparacion de derivados de sulfamida.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2010009753A (es) Composiciones que contienen apoaecuorina y metodos de uso de las mismas.
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
MY150600A (en) Use of opioid antagonists for treating urinary retention
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
EA201001224A1 (ru) Химические соединения, композиции и способы их использования
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
ZA201008160B (en) Compositions for the treatment of hair loss
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
MX2009013126A (es) Nuevos compuestos 892.

Legal Events

Date Code Title Description
FG Grant or registration